Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Has Abenomics Been a Success for Japan’s Economy?
17:16 - Ajay Kapur, Asia-Pacific equity strategist at Bank of America Merrill Lynch, examines the impact of Abenomics on Japan’s economy and currency. He speaks on “Bloomberg Surveillance.” (Source: Bloomberg)
  • India, China Lead Global Rescue Efforts in Nepal
  • Greek Polls Reflect Uncertainty, Insecurity: Panagopoulos
  • Nepal in Race Against Time to Find Quake Survivors